This Parker-Hannifin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Exodus Movement ( AMEX:EXOD ) , ICU Medical ( NASDAQ:ICUI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Wells Fargo initiated coverage on Revolution Medicines, Inc.
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus
Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors - KalVista Pharmaceuticals ( NASDAQ:KALV ) , Metagenomi ( NASDAQ:MGX )
EMERYVILLE, Calif., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Metagenomi, Inc. MGX ( the "Company" ) , a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to ...
Royalty Pharma ( RPRX ) Q2 Receipts Up 20%
Royalty Pharma Plc ( NASDAQ:RPRX ) , a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts-its closest revenue proxy-rose 11% to $672 million but landed just under the $672.99 million analyst ...
Tango ( TNGX ) Q2 Revenue Drops 52%
Tango Therapeutics ( NASDAQ:TNGX ) , a biotechnology firm advancing targeted oncology therapies, posted its second quarter results on August 5, 2025. The highlight of the release was a steep decline in GAAP revenue, well below consensus, along with a larger net loss compared to analyst ...
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
- First patient dosed in combination trial of TNG462 and Revolution Medicines RAS ( ON ) inhibitors ...
Wall Street Analysts Believe Revolution Medicines ( RVMD ) Could Rally 90.58%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 90.6% in Revolution Medicines (RVMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib - Revolution Medicines ( NASDAQ:RVMD )
Breakthrough Therapy Designation granted to elironrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor
This GitLab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - GitLab ( NASDAQ:GTLB ) , Amrize ( NYSE:AMRZ )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Piper Sandler analyst Derek Podhaizer initiated coverage on Select Water Solutions, Inc.
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates
REDWOOD CITY, Calif. and SAN DIEGO, July 09, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( Nasdaq: RVMD ) , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, and Iambic Therapeutics, a clinical-stage life science and technology ...
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS ( ON ) Inhibitors with Ivonescimab in RAS Mutant Tumors - Summit Therapeutics ( NASDAQ:SMMT ) , Revolution Medicines ( NASDAQ:RVMD )
REDWOOD CITY, Calif. and MIAMI, June 30, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. RVMD, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc.
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS ( ON ) Inhibitors with Ivonescimab in RAS Mutant Tumors
REDWOOD CITY, Calif. and MIAMI, June 30, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( Nasdaq: RVMD ) , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc. ( Nasdaq: SMMT ) , a biopharmaceutical ...
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
BOSTON, June 27, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ: TNGX ) , a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the Phase 1/2 trial of TNG462 and ...
Revolution Medicines To Advance Lead Cancer Drug With Funding Worth $2B - Royalty Pharma ( NASDAQ:RPRX ) , Revolution Medicines ( NASDAQ:RVMD )
The deal includes up to $1.25 billion in royalties and $750M in corporate debt for daraxonrasib. Royalty rate on sales over $8 billion drops to zero under 15-year funding agreement. See how Matt Maley is positioning for global volatility, sector rotations, and macro shifts-live this Wednesday, ...
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
NEW YORK, June 24, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan of up to $750 million.
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion - Royalty Pharma ( NASDAQ:RPRX )
Up to $1.25 billion ( $250 million upfront ) of synthetic royalty funding and up to $750 million in secured debt Innovative partnership enables Revolution Medicines to retain control over pipeline development and global commercialization of daraxonrasib
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS ( ON ) Inhibitor Portfolio for Patients with RAS-Addicted Cancers - Revolution Medicines ( NASDAQ:RVMD )
Flexible funding provides $2 billion in committed capital comprised of up to $1.25 billion of synthetic royalty and up to $750 million in corporate debt Company moving forward with independent global commercialization strategy to prioritize patient reach and maximize shareholder value
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations
REDWOOD CITY, Calif., June 23, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( Nasdaq: RVMD ) , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S.
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
- Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected ...
Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday - AppLovin ( NASDAQ:APP ) , Alvotech ( NASDAQ:ALVO )
U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Thursday. Shares of Groupon, Inc. GRPN rose sharply during Thursday's session after the company reported better-than-expected first-quarter financial results.
TV STARS WALK THE WALK FROM COAST TO COAST AT PANCAN PURPLESTRIDE, THE ULTIMATE WALK TO END PANCREATIC CANCER
Reality Star Joan Vassos, "Star Trek" Team, Days of our Lives' Martha Madison & Cast Members and Lisa Niemi Swayze Take Steps to Raise Funds and Awareness for Pancreatic Cancer
Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday? - Revolution Medicines ( NASDAQ:RVMD )
Zoldonrasib showed a 61% objective response rate and 89% disease control rate in NSCLC patients at 1200 mg QD. Most treatment-related side effects were mild, with a 98% mean dose intensity and no dose-limiting toxicities observed. Don't face extreme market conditions unprepared.
Revolution Medicines Presents Initial Data from Zoldonrasib ( RMC-9805 ) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting - Revolution Medicines ( NASDAQ:RVMD )
REDWOOD CITY, Calif., April 27, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc.
Revolution Medicines Presents Initial Data from Zoldonrasib ( RMC-9805 ) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
Zoldonrasib, a RAS ( ON ) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancer Zoldonrasib, a RAS ( ON ) G12D-selective inhibitor, demonstrated acceptable ...
Revolution Medicines to Participate in April 2025 Investor Conferences - Revolution Medicines ( NASDAQ:RVMD )
REDWOOD CITY, Calif., March 31, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. RVMD, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A.
Does Revolution Medicines ( RVMD ) Have the Potential to Rally 74.05% as Wall Street Analysts Expect?
The mean of analysts' price targets for Revolution Medicines (RVMD) points to a 74.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference - Revolution Medicines ( NASDAQ:RVMD )
REDWOOD CITY, Calif., Jan. 29, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. RVMD, a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A.
Keros Therapeutics ( KROS ) Soars 5.1%: Is Further Upside Left in the Stock?
Keros Therapeutics (KROS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Down -7.83% in 4 Weeks, Here's Why Revolution Medicines ( RVMD ) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Revolution Medicines (RVMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
Revolution Medicines ( RVMD ) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Revolution Medicines (RVMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Is John Hancock Multifactor Small Cap ETF ( JHSC ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
Underwriters' full exercise of option brings gross proceeds to $862.5 million Underwriters' full exercise of option brings gross proceeds to $862.5 million ...
Should John Hancock Multifactor Small Cap ETF ( JHSC ) Be on Your Investing Radar?
Style Box ETF report for ...
Top 3 Health Care Stocks That Could Blast Off In December - Elanco Animal Health ( NYSE:ELAN ) , Revolution Medicines ( NASDAQ:RVMD )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
REDWOOD CITY, Calif., Dec. 03, 2024 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( Nasdaq: RVMD ) , a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the pricing of 14,130,436 shares of its common stock at a public ...
Revolution Medicines Announces Commencement of Public Offering of Common Stock
REDWOOD CITY, Calif., Dec. 02, 2024 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( Nasdaq: RVMD ) , a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has commenced an underwritten public offering to sell up to ...
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates - NovoCure ( NASDAQ:NVCR ) , Mondee Hldgs ( NASDAQ:MOND )
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Monday. The Dow traded down 0.34% to 44,759.96 while the NASDAQ gained 1.03% to 19,416.22. The S&P 500 also rose, gaining, 0.26% to 6,047.97. Communication services shares jumped by 1% on Tuesday.
Stellantis, PG&E And Other Big Stocks Moving Lower In Monday's Pre-Market Session - BARK ( NYSE:BARK ) , Erasca ( NASDAQ:ERAS )
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday. Shares of Stellantis N.V. STLA fell sharply in today's pre-market trading.
Revolution Medicines Provides Clinical Updates from its RAS ( ON ) Inhibitor Portfolio
Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute 302 clinical trial ...
Revolution Medicines to Host RAS ( ON ) Inhibitor Clinical Update Webcast on December 2, 2024 - Revolution Medicines ( NASDAQ:RVMD )
REDWOOD CITY, Calif., Nov. 27, 2024 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. RVMD, a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide clinical updates from its RAS ( ON ) ...
Revolution Medicines to Host RAS ( ON ) Inhibitor Clinical Update Webcast on December 2, 2024
REDWOOD CITY, Calif., Nov. 27, 2024 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( Nasdaq: RVMD ) , a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide clinical updates from ...
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
First clinical results for RMC-9805, a RAS ( ON ) G12D-selective inhibitor, demonstrate encouraging tolerability and antitumor activity in patients with ...
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Encouraging progression-free survival and overall survival profile ...
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
REDWOOD CITY, Calif., Oct. 21, 2024 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( Nasdaq: RVMD ) , a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the first patient has been dosed in RASolute 302, a Phase 3 ...
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
Pancreatic ductal adenocarcinoma ( PDAC ) data from RMC-6236 ( RAS ( ON ) multi-selective inhibitor ) and RMC-9805 ( RAS ( ON ) G12D-selective inhibitor ) monotherapy studies to be featured in two late-breaking presentations Pancreatic ductal adenocarcinoma ( PDAC ) data from RMC-6236 ( RAS ( ON ...
Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company - Codexis ( NASDAQ:CDXS )
Company raises $31 million through ATM, bringing cash runway into 2027 New additions to leadership in technical operations, finance and intellectual property prepare Codexis for the next phase of growth REDWOOD CITY, Calif., Oct. 02, 2024 ( GLOBE NEWSWIRE ) -- Codexis, Inc.
Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company
Company raises $31 million through ATM, bringing cash runway into ...
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
SAN FRANCISCO, Sept. 16, 2024 ( GLOBE NEWSWIRE ) -- 89bio, Inc. ( Nasdaq: ETNB ) , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa ...
Collegium Pharmaceutical ( COLL ) Earnings Expected to Grow: Should You Buy?
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter - Revolution Medicines ( NASDAQ:RVMD )
As of July 16, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when ...
